drugset

drugset / Trial / NCT06140953

Benefits of Trimetazidine in MASLD Patients

NCT06140953 ↗

Phase 2 Completed 60 enrolled October 6 University

RandomizedParallel-groupDouble-blindTreatment

Summary

Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD

Timeline

Start: 2023-12-10
Primary completion: 2024-06-01
Completion: 2024-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trimetazidine	Small molecule	20 mg	—

Indications